TRX BIOSCIENCES LIMITED - Key Persons
Dr Andy Richards CBE has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia and the Babraham Research Campus and is a Director of Ieso Digital Health, Cancer Research Technology (commercial board of CR-UK) and Owlstone Medical. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a director of The Scale Up Institute.
Dan brings >20 years experience in biopharma technology development, commercialisation, entrepreneurship & business development. As founding CEO of Nuformix, Dan oversaw seed round to IPO securing >20x for founder investors. completing multiple out-licensing & financing transactions whilst transitioning NFX from technology development to product development. Dan is an Executive Director of TRx Biosciences Limited.
Robin has over 30 years in Biopharma R&D commercialisation with proven success as a drug developer & entrepreneur, illustrated by the multiple marketed products and successful exits (e.g. Seebri, Arakis) spanning his career to date. Robin has particular scientific expertise in novel biology exploitation via the development of high-value, low-risk products. Robin is an Executive Director of TRx Biosciences Limited.
With over 20 years experience in biopharma product development, John has progressed numerous R&D programmes from concept to market (e.g. Flarin™️). John has developed deep experience in non-clinical & clinical development & regulatory affairs. His scientific expertise spans biology, toxicology, pharmacology, pharmacokinetics & pharmaceutics. John is an Executive Director of TRx Biosciences Limited.